Explaining the unexplained leucopenia in azathioprine treatment [1]

Annals of Gastroenterology

Volumn 19, Issue 2, 2006, Pages 141-142

  Katsanos, K H ^a   Tsianos, Epameinondas V ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Azathioprine; Inflammatory bowel disease; Leucopenia

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; COTRIMOXAZOLE; DIURETIC AGENT; MESALAZINE; SALAZOSULFAPYRIDINE; THIOPURINE METHYLTRANSFERASE; XANTHINE OXIDASE;

DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG METABOLISM; ENTERITIS; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC VARIABILITY; GENOTYPE; HUMAN; INCIDENCE; LETTER; LEUKOPENIA;

EID: 34548531004     PISSN: 11087471     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (6)

1. Lennard L. TPMT in the treatment of inflammatory bowel disease with azathioprine. Gut 2003; 52:767-768
2. Neurath MF, Kiesslich R, Fischer C, et al. Measurment of 6-thioguanosine mono- di- and triphosphates for monitoring of azathioprine therapy in IBD. Gastroenterology 2003; S1421:A214
3. Gearry RB, Barclay ML, Burt MJ, et al. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18:395-400
4. Black AJ, McLeod HL, Capell HA, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998; 129:716-718
5. Cheung ST, Allan RN. Mistaken identity: misclassification of TPMT phenotype following blood transfusion. Eur J Gastroenterol Hepatol 2003; 15:1245-1247
6. Sandborn WJ. Pharmacogenomics and IBD:TPMT and thiopurines. Inflamm Bowel Dis 2004; 10:148-158